Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Penile Diseases
Interventions: RestoreX PTT - randomized and open label, RestoreX PTT - open label phase only; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Embolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin overlapping with and followed by VKA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 4,833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 23
States / cities: Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more

Conditions: Opioid Overdose
Interventions: 16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray; Combination Product
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Post Traumatic Stress Disorder
Interventions: Iloperidone, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pancreatic Insufficiency, Pancreatic Cancer, Pancreatic Enzyme Abnormality
Interventions: Pancrelipase, Placebo Oral Capsule; Drug
Lead sponsor: Massimo Raimondo, M.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Basal Cell Carcinoma
Interventions: ALA, PDT; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Leukemia, Lymphocytic, Chronic
Interventions: alvocidib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 8 more

Conditions: Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Talimogene Laherparepvec, Radiation, Cisplatin; Biological · Radiation · Drug
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Canton, Ohio + 2 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST); Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cigarette Smoking
Interventions: E-cigarette (EC), Nicotine Replacement Therapy (NRT), Harm-Reduction Counseling, Ecological Momentary Intervention (EMI) Text Messaging; Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol Use Disorder, Insomnia
Interventions: Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence; Drug · Behavioral · Device
Lead sponsor: Sterling McPherson; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions: ELI-002 7P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment; Drug
Lead sponsor: Clinical Research Center of the Carolinas; Other
Eligibility: 2 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Alzheimer's Disease
Interventions: MemorEM; Device
Lead sponsor: NeuroEM Therapeutics, Inc.; Industry
Eligibility: 63 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rheumatoid Arthritis -Exposure During Pregnancy
Interventions: Sarilumab SAR153191 (REGN88); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
Interventions: DS-1055a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior, Challenging Behavior
Interventions: Propranolol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 12 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Type 2 Diabetes Mellitus, Overweight
Interventions: TANTALUS(TM) System; Device
Lead sponsor: MetaCure (USA), Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: La Jolla / San Diego, California • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Acute Myeloid Leukemia in Children, Myeloproliferative Neoplasm
Interventions: MRF with neurocognative studies; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions: Pirfenidone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol Drinking
Interventions: Enhanced Usual Care (pre-operative), Preoperative Virtual Health Coaching, Usual surgical care (post-operative), Postoperative Virtual Health Coaching, On-Track (Post-operative); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 75 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Fontan Circulation
Interventions: Sildenafil, Placebo, Sildenafil 2, Placebo 2; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Efficacy of Penile Traction Therapy Using a Novel Device

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Effect of Insulin Lowering on Lipogenesis

E-cigarettes for Harm Reduction Among Smokers With Serious Mental Illness

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

An Observational Study on Sarilumab-exposed Pregnancies

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Propranolol for Challenging Behaviors in Autism

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

Alcohol Screening and Preoperative Intervention Research Study - 2

The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation